Press release
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced poster
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced poster presentations of data from IMerge, the Company’s Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat vs. placebo in patients with lower risk myelodysplastic syndromes (MDS) at the eleventh annual Society of Hematologic Oncology Annual Meeting (SOHO) held in Houston, Texas and virtually.\n\n\n“For imetelstat-treated patients in the IMerge Phase 3 trial, the durability of transfusion independence, substantial increases in hemoglobin, robust treatment effect across subgroups and improvement in fatigue, along with a manageable safety profile, represent, we believe, an unparalleled clinical benefit in lower risk MDS,” said Faye Feller, M.D., Executive Vice President, Chief Medical Officer of Geron. “It was particularly meaningful for these data to be presented at SOHO, where there was a broad array of professionals who touch the lives of patients with lower risk MDS.”\n\n\nThe following posters presented at SOHO reflected data presented at the European Hematology Association annual meeting in June 2023:\n\n\n\nMDS-572: Continuous Transfusion Independence with Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III\n\n\n\nMDS-604: Improvement of Patient-Reported Fatigue in IMerge Phase III Trial of Imetelstat vs Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents\n\n\n\nMDS-605: Disease Modifying Activity of Imetelstat in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III\n\n\n\nThe posters are available under the Publications section of Geron’s website: https://www.geron.com/research-and-development/publications/.\n\n\nAs previously reported, in the IMerge Phase 3 clinical trial, the primary endpoint of 8-week transfusion independence (TI) was significantly higher with imetelstat vs. placebo (p","length":3081,"tagName":"div"}]